Immunomedics, Inc. (NASDAQ: IMMU) shares were plunging Friday following an adverse regulatory development. Immunomedics announced Thursday after the market close the FDA issued a complete response letter for its BLA for sactuzumab govitecan, its investigational candidate for metastatic triple-negative breast cancer, or TNBC, in patients who have previously received at...